A Randomized, Double-blind, Single-centre, Two-period Cross-over, Placebo-controlled Trial on Safety and Efficacy in Patients with Genetically Proven CADASIL
Latest Information Update: 04 Mar 2025
At a glance
- Drugs FPF 1070 (Primary)
- Indications CADASIL
- Focus Therapeutic Use
- Acronyms CERICA
- Sponsors EVER Neuro Pharma
- 25 Feb 2025 Status changed from recruiting to active, no longer recruiting.
- 05 Dec 2023 Status changed from not yet recruiting to recruiting.
- 06 Sep 2023 Planned initiation date changed from 1 Apr 2023 to 1 Oct 2023.